arsenic trioxide has been researched along with Recrudescence in 136 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (7.35) | 18.2507 |
| 2000's | 66 (48.53) | 29.6817 |
| 2010's | 52 (38.24) | 24.3611 |
| 2020's | 8 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Y; Xu, Q; Yu, J; Zhang, K | 1 |
| Buettner, R; Burnett, J; Ghoda, L; Hoang, DH; Kuo, YH; Marcucci, G; Nguyen, LXT; Pullarkat, V; Rosen, ST; Valerio, M; Zhang, B | 1 |
| Ahn, MJ; Bae, SH; Bang, SM; Cho, EK; Choi, JH; Chong, SY; Hyun, MS; Jo, DY; Kim, B; Kim, BS; Kim, CS; Kim, DY; Kim, H; Kim, HJ; Kim, HS; Kim, I; Kim, SH; Kwon, H; Lee, JH; Lee, KH; Lee, MH; Lee, WS; Min, YJ; Moon, HN; Mun, YC; Nam, SH; Oh, D; Park, JH; Park, KT; Park, SY; Park, YH; Ryoo, HM; Seo, JJ; Seong, CM; Yoon, HJ; Yoon, SS; Zang, DY | 1 |
| Yanada, M | 1 |
| Abraham, A; Balasubramanian, P; Fouzia, NA; George, B; Kulkarni, UP; Lionel, S; Mani, T; Mathews, V; Nair, SC; Selvarajan, S | 1 |
| Chan, SY; Dang, CC; Guan, YK; Lau, NS | 1 |
| He, J; Wang, L; Yan, X | 1 |
| Fukuda, K; Iimura, Y; Isshiki, T; Nagasawa, T; Sato, Y; Suzuki, S; Yoshizawa, Y | 1 |
| Akasaka, T; Honjo, G; Minoda, S; Nakagawa, M; Ohno, H; Okanoue, Y | 1 |
| Kayser, S; Platzbecker, U; Schlenk, RF | 1 |
| Ades, L; Bally, C; Berthier, C; Cassinat, B; de Thé, H; Fenaux, P; Hirsch, P; Jollivet, F; Kogan, S; Lehmann-Che, J; Letouzé, E; Mozziconacci, MJ; Pigneux, A; Yuan, H | 1 |
| Chen, LM; Gong, S; Liu, X; Liu, Y; Wang, HY; Wang, MC; Xi, JY; Zhang, HY; Zhang, XX | 1 |
| Alfonso, V; Breccia, M; Cicconi, L; Diverio, D; Divona, M; Foa, R; Franceschini, L; Iaccarino, L; Latagliata, R; Lo-Coco, F; Molica, M; Ottone, T; Rizzo, M; Voso, MT | 1 |
| Chen, Y; Deng, Y; Ding, B; He, Z; Ling, L; Shi, Y; Song, L; Tao, S; Wang, C; Yu, L | 1 |
| Bergua, J; Boluda, B; Brunet, S; Calasanz, MJ; Cervera, J; Chillón, MC; de laSerna, J; Esteve, J; Fernández, I; Gil, C; González-Campos, J; González-Sanmiguel, JD; Holowiecka, A; Krsnik, I; Labrador, J; Lowenberg, B; Luño, E; Manso, F; Montesinos, P; Moreno, MJ; Pérez-Encinas, M; Ribera, JM; Salamero, O; Sanz, MA; Sobas, M; Tormo, M; Vellenga, E | 1 |
| Adès, L; Avvisati, G; Burnett, AK; Chen, SJ; Döhner, H; Estey, EH; Fenaux, P; Iland, H; Kantarjian, H; Lengfelder, E; Lo-Coco, F; Löwenberg, B; Mathews, V; Montesinos, P; Naoe, T; Platzbecker, U; Ravandi, F; Rego, E; Russell, NH; Sanz, MA; Tallman, MS | 1 |
| Alfonso, V; Arcese, W; Baer, C; Cicconi, L; Del Principe, MI; Divona, M; Falconi, G; Ferrantini, A; Forghieri, F; Haferlach, T; Iaccarino, L; Lavorgna, S; Lo-Coco, F; Ottone, T; Travaglini, S; Usai, M; Venditti, A; Voso, MT | 1 |
| Chao, NJ; de Castro, CM; Diehl, LF; Gasparetto, C; Gockerman, JP; Held, LA; Horwitz, ME; Long, GD; Moore, JO; Rizzieri, D | 1 |
| Asou, N; Fujita, H; Hyo, R; Inaguma, Y; Ishigatsubo, Y; Iwanaga, M; Izumi, T; Kiyoi, H; Matsuda, M; Miyawaki, S; Miyazaki, Y; Nakaseko, C; Naoe, T; Nomura, S; Ohnishi, K; Ohtake, S; Okada, M; Shinagawa, K; Takeshita, A; Yamauchi, T | 1 |
| Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Tong, H; Tong, Y | 1 |
| Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Suo, S; Tong, H; Tong, Y; Yu, W | 1 |
| Ansari, M; Bourquin, JP; Gumy-Pause, F; Huezo-Diaz, P; Judas, C; Mattiello, V; Rock, N | 1 |
| Altman, JK; Cull, EH | 1 |
| Au, WY; Cheung, WW; Gill, H; Kwong, YL; Lee, EY | 1 |
| Cao, F; Lan, W; Li, D; Li, J; Li, L; Li, Y; Liu, X; Meng, R; Shi, C; Wang, H; Yang, B; Zhang, Y; Zhang, Z; Zhao, H; Zhou, J | 1 |
| Bally, C; de Thé, H; Lehmann-Che, J | 1 |
| Fujita, H | 1 |
| Barakat, S; Couban, S; Lachaine, J; Mathurin, K | 1 |
| Hatakeyama, N; Hori, T; Igarashi, K; Inazawa, N; Noguchi, H; Sasaki, M; Somekawa, Y; Suzuki, N; Tsutsumi, H; Yamamoto, M | 1 |
| Ades, L; Breccia, M; Cassinat, B; Di Bona, E; Fenaux, P; González-Sanmiguel, JD; Görlich, D; Grimwade, D; Hofmann, WK; Huerta, AJ; Kishore, B; Lambert, JF; Lehmann, S; Lengfelder, E; Lo-Coco, F; Montesinos, P; Nloga, AM; Pagoni, M; Ramadan, SM; Sanz, M; Sauerland, MC; Schmidt, A | 1 |
| Hong, L; Kong, D; Qiao, Z; Shi, W; Sun, G; Zhang, Y; Zhao, H; Zhao, M | 1 |
| Abraham, A; Aiyaz, M; Alex, AA; Balasubramanian, P; Chandy, M; Chendamarai, E; Chomienne, C; Ganesan, S; George, B; Janet, NB; Kamath, V; Lakshmi, KM; Mathews, V; Mugasimangalam, R; Mullapudi, N; Nair, SC; Nellickal, AJ; Padua, RA; Srivastava, A; Srivastava, V; Viswabandya, A | 1 |
| Jin, J; Li, F; Lu, Y; Mai, W; Meng, H; Mu, Q; Pei, R; Qian, W; Tong, H; Yu, M; Zhao, X | 1 |
| Allen, SL; Altman, JK; Cortes, JE; Coutre, S; Di Bona, E; Kantarjian, H; Lo-Coco, F; Ravandi, F; Sanford, D; Sanz, MA; Wetzler, M | 1 |
| He, J; Jin, J; Lou, Y; Ma, Y; Mai, W; Meng, H; Pan, H; Qian, W; Sun, J; Tong, H; Wang, Y; Ye, X | 1 |
| Breccia, M; Cicconi, L; Lo-Coco, F | 1 |
| Altman, JK; Norsworthy, KJ | 1 |
| Blondeau, S; Bouyer, S; Colin, O; Houeto, JL; Julian, A; Meurin, E; Neau, JP; Puyade, M | 1 |
| Alimoghaddam, K; Devlin, S; Douer, D; Esteve, J; Ganzel, C; Ghavamzadeh, A; Kuk, D; Mathews, V; Mohty, M; Nagler, A; Polge, E; Rowe, JM; Tallman, MS; Wang, H; Weisdorf, D; Zhang, MJ | 1 |
| Atsuta, Y; Emi, N; Gotoh, M; Hashimoto, H; Henzan, H; Ichinohe, T; Kanamori, H; Kanda, Y; Kohno, A; Kurokawa, M; Mori, T; Murata, M; Nishikawa, A; Sawa, M; Takami, A; Tomita, N; Watakabe, K; Yanada, M; Yano, S | 1 |
| Litzow, MR | 1 |
| Ammatuna, E; Lo-Coco, F; Montesinos, P; Sanz, MA | 1 |
| Au, WY; Fong, BM; Kwong, YL; Tam, S | 2 |
| Horikoshi, A; Iriyama, N; Kaise, T; Miyashita, SI; Shikino, O; Toyoda, H; Yoshino, Y; Yuan, B | 1 |
| Amadori, S; Ammatuna, E; Cavaliere, A; Divona, M; Lo-Coco, F; Scambia, G | 1 |
| Kurokawa, M; Nagai, S; Takahashi, T | 1 |
| Bajorin, DF; Halabi, S; Small, E | 1 |
| Balasubramanian, P; Chandy, M; Chendamarai, E; George, B; Lakshmi, KM; Mathews, V; Srivastava, A; Thirugnanam, R; Viswabandya, A | 1 |
| Chen, Y; Gao, J; Gu, L; Jia, C; Li, Q; Ma, Z; Wu, X; Zhou, C; Zhu, Y | 1 |
| Blinder, R; Chang, P; Galinsky, I; Ho, VT; Housman, E; Kesari, S; Lane, SW; Mullally, A; Stone, RM | 1 |
| García Salido, A; Lassaletta Atienza, A; Madero López, L; Moreno Tejero, ML; Sevilla Navarro, J | 1 |
| Abraham, A; Balasubramanian, P; Chandy, M; Chendamarai, E; Desire, S; George, B; Lakshmi, KM; Mathews, V; Shaji, RV; Srivastava, A; Thirugnanam, R; Viswabandya, A | 1 |
| Ambaglio, I; Bernasconi, P; Castagnola, C; Corso, A; Lazzarino, M; Rossi, M; Zappasodi, P | 1 |
| Hasan, SK; Lo-Coco, F | 1 |
| Lo-Coco, F; Sanz, MA | 1 |
| Ebinger, M; Feuchtinger, T; Gessler, P; Handgretinger, R; Hildenbrand, S; Lang, P; Scheel-Walter, HG; Schwarze, CP | 1 |
| Jeong, KH; Park, TS; Yoon, HS | 1 |
| Breccia, M; Cicconi, L; Giannì, L; Latagliata, R; Lo-Coco, F; Minotti, C | 1 |
| Au, WY; Chan, GC; Ha, SY; Kwong, YL; Lee, V; Li, CK; Yau, J; Yuen, HL | 1 |
| Au, WY; Kumana, CR; Kwong, YL; Lau, JS; Lee, HK; Lin, SY; Liu, H; Yeung, DY | 1 |
| Inoue, A; Kawakami, C; Takitani, K; Tamai, H | 1 |
| Kwong, YL | 1 |
| Batár, P; Kiss, A; Rejto, L; Reményi, G; Szász, R; Telek, B; Udvardy, M; Ujj, ZÁ | 1 |
| Chen, SJ; Chen, Z; Li, JM; Mi, JQ; Shen, ZX | 1 |
| Breccia, M; Lo-Coco, F | 1 |
| Huang, H; Liu, H; Qin, Y; Teng, R; Xu, M; Xu, R; Yang, L; You, X | 1 |
| Fan, S; Han, L; Han, X; Hu, L; Li, J; Li, L; Li, X; Li, Y; Lv, C; Su, Y; Wang, S; Zhang, X; Zhang, Y; Zhang, Z; Zhao, H; Zhao, Y; Zhou, J | 1 |
| Emi, N | 1 |
| Chim, CS; Kam, S; Kwong, YL; Lam, CC; Man, C; Wong, KF | 1 |
| Au, WY; Chim, CS; Kwong, YL; Pang, A; Wai Lie, AK | 1 |
| Cairoli, R; Di Bona, E; Marenco, P; Montillo, M; Morra, E; Nosari, A; Tedeschi, A; Tresoldi, E | 1 |
| Hirayama, Y; Matsunaga, T; Niitsu, Y; Sagawa, T; Sakamaki, S; Takayanagi, N; Tsuji, Y | 1 |
| Buzyn, A; Cassinat, B; Chomienne, C; Cimerman, P; Daniel, MT; de Thé, H; Degos, L; Delarue, R; Dombret, H; Fermand, JP; Hermine, O; Lebbé, G; Poupon, J; Raffoux, E; Réa, D; Rousselot, P; Taksin, AL; Tibi, A | 1 |
| Grigg, A; Kimber, R; Szer, J | 1 |
| Arnulf, B; Bazarbachi, A; Brouet, JC; Damaj, G; de Thé, H; Degos, L; Delarue, R; Dombret, H; Fermand, JP; Hermine, O; Lefrère, F; Poupon, J; Rousselot, P; Varet, B | 1 |
| Gibson, AD; Klem, J; Price, N; Reddy, GK | 1 |
| Avvisati, G; Breccia, M; Carmosino, I; Finolezzi, E; Latagliata, R; Lo Coco, F; Petti, MC | 1 |
| Dryden, MJ; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, HM; Pierce, S; Ratnam, S; Tsimberidou, AM; Whitman, GJ | 1 |
| Berenson, JR; Ferretti, D; Purner, MB; Swift, RA | 1 |
| Cai, L; Cui, J; Gao, S; Jiang, Z; Li, W; Liu, Z; Song, Y; Wang, G; Yang, Y; Yao, C; Yuan, CJ | 1 |
| Berenson, JR; Borad, MJ; Swift, R | 1 |
| Au, WY; Cheung, GT; Kumana, CR; Kwong, YL; Yuen, TW | 1 |
| Asou, N | 1 |
| Fujisawa, S; Kobayashi, M; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Sahara, N; Shigeno, K; Shinjo, K; Takeshita, A | 1 |
| Büchner, T; Hehlmann, R; Lengfelder, E; Saussele, S; Weisser, A | 1 |
| Au, WY; Kwong, YL | 1 |
| Tallman, MS | 2 |
| Alimoghaddam, K; Ghavamzadeh, A; Jahani, M; Rostami, S; Sanaat, Z; Shariftabrizi, A; Tavangar, M; Tavangar, SM | 1 |
| Akioka, T; Hanafusa, T; Hara, S; Oka, T; Tsuji, M; Yamano, T; Yokote, T | 1 |
| Ahn, E; Bach, A; Bouzari, N; Chen, H; Nouri, K; Ricotti, CA | 1 |
| Ades, L; Bordessoule, D; Castaigne, S; Chevret, S; de Botton, S; Degos, L; Dombret, H; Fegueux, N; Fenaux, P; Guerci, A; Kelaidi, C; Link, H; Meyer-Monard, S; Raffoux, E; Rayon, C; Rigal-Huguet, F; Sanz, M; Stoppa, A; Thomas, X; Vekhoff, A | 1 |
| Abou-Jawde, RM; Andresen, S; Baz, R; Hussein, M; Karam, MA; Kelly, M; Reed, J; Walker, E | 1 |
| Kai, T; Kimura, H; Maruyama, Y; Ogawa, K; Sato, H; Shiga, Y | 1 |
| Alimoghaddam, K; Bashash, D; Ghaffari, SH; Ghavamzadeh, A; Rostami, S | 1 |
| Bennett, JM; Dewald, GW; Gallagher, RE; Jain, V; Lee, S; Litzow, MR; Mazza, JJ; Paietta, EM; Racevskis, J; Rousey, SR; Tallman, MS | 1 |
| Ohnishi, K | 1 |
| Chang-chun, W; Jian-xiang, W; Lu-gui, Q; Ming-zhe, H; Qiao-chuan, L; Ren-chi, Y; Wan-jun, S; Xin, L; Yan, L; Yao-zhong, Z; Yun-tao, L; Zeng-jun, L | 1 |
| Berenson, JR; Bessudo, A; Boccia, R; Bozdech, M; Ferretti, D; Flam, M; Jilani, S; Louie, R; Lutzky, J; Moss, R; Patel, R; Russell, K; Siegel, D; Stadtmauer, E; Steis, R; Swift, RA; Talisman Pomeroy, J; Volk, J; Wong, SF; Yeh, HS | 1 |
| Amadori, S; Beksac, M; Sonneveld, P; van Droogenbroeck, J; Wu, KL; Zweegman, S | 1 |
| Büchner, T; Hehlmann, R; Lengfelder, E; Schultheis, B | 1 |
| Ammatuna, E; Lo Coco, F; Sanz, MA | 1 |
| Berenson, JR; Mapes, R; Matous, J; Morrison, B; Swift, RA; Yeh, HS | 1 |
| Aoki, M; Hara, S; Ishitsuka, K; Ogata, K; Suzumiya, J; Tamura, K | 1 |
| Augustyniak, C; Evens, AM; Gordon, LI; Gupta, R; Mehta, J; Ziegler, SL | 1 |
| Adamson, PC; Balis, FM; Blaney, SM; Fox, E; Goodspeed, W; Murgo, AJ; O'Brien, M; Razzouk, BI; Reaman, GH; Widemann, BC; Xiao, S | 1 |
| Aoki, S; Asai, T; Chiba, S; Hangaishi, A; Kanda, Y; Kurokawa, M; Motokura, T; Nagai, S; Ohtomo, K; Oshima, K; Watanabe, T | 1 |
| Levy, M; McLean, TW; Powell, BL; Wofford, MM | 1 |
| Chen, X; Chen, Y; Zhang, L; Zhao, H; Zhu, X; Zou, Y | 1 |
| Craig, CM; Schiller, GJ | 1 |
| Avigan, DE; Bernardi, R; Ikeda, Y; Ito, K; Matsuoka, S; Morotti, A; Pandolfi, PP; Rosenblatt, J; Saglio, G; Teruya-Feldstein, J | 1 |
| Chen, GQ; Chen, SJ; Chen, Y; Chen, Z; Fang, ZW; Li, XS; Ma, J; Ni, JH; Qiu, QY; Shen, ZX; Sun, GL; Tang, W; Wang, YT; Wang, ZY; Xiong, SM; Yang, KQ; Zhang, P; Zhang, TD; Zhou, L; Zhu, J | 1 |
| Kitamura, K; Kiyoi, H; Naoe, T; Ohno, R; Takeshita, A; Tobita, T; Yoshida, H | 1 |
| Calleja, E; Corso, D; Dardashti, LJ; DeBlasio, A; Gabrilove, J; Jhanwar, S; Maslak, P; Pandolfi, PP; Scheinberg, DA; Soignet, SL; Wang, ZG; Warrell, RP | 1 |
| Avvisati, G; Lo Coco, F; Mandelli, F; Nervi, C | 1 |
| Chang, CS; Chen, YC; Chou, WC; Chung, CY; Huang, SF; Huang, SY; Kuo, TL; Shen, MC; Tang, JL; Tien, HF; Wang, CH; Yao, YT | 1 |
| Carmignani, A; Fazzi, R; Galimberti, S; Papineschi, F; Petrini, M; Testi, R | 1 |
| Agis, H; Edelhäuser, M; Fonatsch, C; Geissler, K; Lechner, K; Mitterbauer, G; Seewann, HL; Thalhammer, R; Valent, P; Weltermann, A | 1 |
| Cao, Q; Chen, GQ; Chen, SJ; Chen, Y; Chen, Z; Gu, BW; Gu, FY; Hu, J; Li, JM; Li, XS; Liu, JX; Niu, C; Ren, MY; Shen, ZX; Su, XY; Sun, HP; Wang, ZY; Waxman, S; Wu, W; Xiong, SM; Yan, H; Yang, RR; Yu, T; Yuan, MM; Zeng, XY; Zhang, FQ; Zhang, TD; Zhou, L | 1 |
| Donelli, A; Galimberti, S; Leonardi, G; Luppi, M; Marasca, R; Petrini, M; Torelli, G; Vaccari, P; Zucchini, P | 1 |
| Chang, IY; Huang, MJ; Lin, WY; Sheu, YT | 1 |
| Fujisawa, S; Fujita, Y; Matsui, H; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Satoh, H; Shigeno, K; Shinjo, K; Sugiyama, S; Takeshita, A; Terada, H; Yoshida, H | 1 |
| Miller, KB; Relias, V; Roberts, TF; Schenkein, D; Sprague, K | 1 |
| Chen, G; Chen, S; Chen, Z; Fang, Z; Huang, Y; Li, X; Liu, H; Ni, J; Shen, Z; Wang, Z | 1 |
| Au, WY; Chim, CS; Kwong, YL; Liang, R; Pang, A; Suen, C | 1 |
| Balasubramanian, P; Chandy, M; George, B; Mathews, V; Shaji, RV; Srivastava, A | 1 |
| Chen, J; Chen, SJ; Chen, Z; Li, JM; Li, XS; Liu, YF; Niu, C; Shen, Y; Shen, ZX; Tang, W; Wang, ZY; Wu, F; Wu, W; Xiong, SM; Yan, H; Zeng, XY; Zhao, WL | 1 |
| Adkins, DR; Brown, RA; Curtin, P; DiPersio, JF; Hurd, D; Khoury, H; Ley, TJ; Luger, SM; Ma, MK; Westervelt, P | 1 |
| Hirayama, Y; Ishikawa, K; Ishitani, K; Kondo, A; Koyama, R; Matsunaga, T; Nagai, T; Niitsu, Y; Ohta, H; Sakamaki, S | 1 |
| Douer, D | 1 |
| Han, X; Hu, L; Li, X; Liu, P; Qiu, F; Wang, S; Xiao, Y; Yang, H; Zhang, P; Zhou, J | 1 |
| Au, WY; Chim, CS; Kwong, YL; Liang, R; Lie, AK | 1 |
| Bloomfield, CD; Slack, JL; Tallman, MS; Tricot, G; Waxman, S | 1 |
| Davison, K; Mann, KK; Miller, WH | 1 |
| Dombret, H; Fenaux, P; Soignet, SL; Tallman, MS | 1 |
25 review(s) available for arsenic trioxide and Recrudescence
| Article | Year |
|---|---|
Treatment for relapsed acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Treatment Outcome; Tretinoin | 2022 |
Does acute promyelocytic leukemia patient with the STAT5B/RARa fusion gene respond well to decitabine?: A case report and literature review.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Asian People; Consolidation Chemotherapy; Cytarabine; Decitabine; Drug Therapy, Combination; Female; Hospitalization; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Recurrence; Retinoic Acid Receptor alpha; STAT5 Transcription Factor; Treatment Outcome; Tretinoin | 2020 |
Management of patients with acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Electrocardiography; Female; Fetus; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Leukocytosis; Neoplasms, Second Primary; Pregnancy; Recurrence; Renal Dialysis; Renal Insufficiency; Tretinoin | 2018 |
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.
Topics: Aged; Arsenic Trioxide; Disease Management; Female; Hemorrhagic Disorders; Humans; Leukemia, Promyelocytic, Acute; Practice Guidelines as Topic; Pregnancy; Recurrence; Tretinoin | 2019 |
Contemporary treatment of APL.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin | 2014 |
[Treatment for acute promyelocytic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Clinical Trials, Phase III as Topic; Consolidation Chemotherapy; Disseminated Intravascular Coagulation; Gene Fusion; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Molecular Targeted Therapy; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Recurrence; Remission Induction; Retinoic Acid Receptor alpha; Tetrahydronaphthalenes; Transcription Factors; Tretinoin; Tumor Suppressor Proteins | 2014 |
Current standard treatment of adult acute promyelocytic leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Early Diagnosis; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Stem Cell Transplantation; Tretinoin | 2016 |
Optimal treatment strategies for high-risk acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blood Coagulation Disorders; Disease Management; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Treatment Outcome; Tretinoin | 2016 |
Arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence | 2008 |
Beneficial and adverse effects of molecularly targeted therapies for acute promyelocytic leukemia in central nervous system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Central Nervous System Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin | 2009 |
Modern approaches to treating acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin | 2011 |
Pathogenesis and treatment of leukemia: an Asian perspective.
Topics: Arsenic Trioxide; Arsenicals; Asian People; Cell Proliferation; Humans; Leukemia; Leukemia, Large Granular Lymphocytic; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin | 2012 |
[Current treatment of acute myeloid leukaemia in adults].
Topics: Age Factors; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mitoxantrone; Molecular Targeted Therapy; Oxides; Prognosis; Pyrazines; Recurrence; Transplantation, Homologous; Treatment Outcome; Tretinoin | 2012 |
How to manage acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Transformation, Neoplastic; Central Nervous System Neoplasms; Consolidation Chemotherapy; Drug Synergism; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Oxides; Recurrence; Tretinoin | 2012 |
Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease.
Topics: Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin | 2012 |
An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Remission Induction; Treatment Outcome; Tretinoin | 2004 |
Treatment concepts of acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Prognosis; Recurrence; Risk Factors; Stem Cell Transplantation; Thrombosis; Translocation, Genetic; Transplantation, Homologous; Tretinoin | 2005 |
[Therapeutic strategies for patients with relapsed acute promyelocytic leukemia].
Topics: Aminoglycosides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Leukemia, Promyelocytic, Acute; Oxides; Practice Guidelines as Topic; Recurrence; Remission Induction; Tetrahydronaphthalenes; Tretinoin | 2006 |
[Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Risk Factors; Time Factors | 2007 |
Acute myeloid leukemia in the elderly: conventional and novel treatment approaches.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Azacitidine; Clofarabine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Oxides; Recurrence; Sulfonamides | 2008 |
Advances in the treatment of relapsed acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Combined Modality Therapy; Humans; Leukemia, Promyelocytic, Acute; Neoplasm, Residual; Oxides; Recurrence; Tretinoin | 2002 |
Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Oxides; Recurrence; Remission Induction; Survival Analysis; Treatment Outcome; Tretinoin | 2002 |
Introduction.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Tretinoin | 2002 |
Arsenic trioxide: mechanisms of action.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Division; Glutathione; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neovascularization, Pathologic; Oncogene Proteins, Fusion; Oxides; Recurrence | 2002 |
Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy.
Topics: Antineoplastic Agents; Antineoplastic Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis; Randomized Controlled Trials as Topic; Recurrence | 2002 |
24 trial(s) available for arsenic trioxide and Recrudescence
| Article | Year |
|---|---|
A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oxides; Pyrazines; Recurrence | 2013 |
Arsenic trioxide and mannitol for the treatment of acute promyelocytic leukemia relapse in the central nervous system.
Topics: Adolescent; Adult; Arsenic Trioxide; Arsenicals; Blood-Brain Barrier; Central Nervous System Neoplasms; Child; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Male; Mannitol; Middle Aged; Oxides; Recurrence; Remission Induction; Young Adult | 2014 |
A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lymphoma; Male; Middle Aged; Oxides; Recurrence; Treatment Outcome | 2015 |
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Biomarkers, Tumor; Cardiovascular Diseases; Cell Differentiation; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; Drug Resistance, Neoplasm; Febrile Neutropenia; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Salvage Therapy; Tetrahydronaphthalenes; Tretinoin | 2015 |
Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium | 2009 |
Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Follow-Up Studies; Hair; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Nails; Oxides; Recurrence; Remission Induction; Time Factors; Treatment Outcome | 2010 |
Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cytarabine; Daunorubicin; Disease-Free Survival; Dyspepsia; Female; Follow-Up Studies; Headache; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Remission Induction; Time Factors; Treatment Outcome; Tretinoin | 2011 |
Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Statistics, Nonparametric; Survival Rate; Treatment Outcome; Tretinoin | 2003 |
Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma.
Topics: Adult; Anti-HIV Agents; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Human T-lymphotropic virus 1; Humans; Injections, Intravenous; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; Middle Aged; Oxides; Prognosis; Recurrence; Treatment Outcome; Zidovudine | 2004 |
A prospective, open-label safety and efficacy study of combination treatment with melphalan, arsenic trioxide, and ascorbic acid in patients with relapsed or refractory multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Disease Progression; Drug Resistance, Neoplasm; Humans; Melphalan; Middle Aged; Multiple Myeloma; Oxides; Prospective Studies; Recurrence; Time Factors; Treatment Outcome | 2004 |
Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Female; Humans; Japan; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Treatment Outcome | 2005 |
Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Disease Progression; Female; Follow-Up Studies; Humans; Immunohistochemistry; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Neovascularization, Pathologic; Oxides; Recurrence; Remission Induction; Survival Rate; Time Factors; Treatment Outcome | 2006 |
Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline- based chemotherapy: the European APL group experience (APL 91 and APL 93 trials).
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Europe; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prognosis; Recurrence; Risk Factors; Treatment Outcome; Tretinoin | 2006 |
Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oxides; Recurrence; Vitamins | 2006 |
A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Oxides; Patient Selection; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Treatment Outcome | 2006 |
Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Creatinine; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Oxides; Prospective Studies; Recurrence; Survival Analysis; Treatment Outcome | 2006 |
Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Dexamethasone; Drug Therapy, Combination; Follow-Up Studies; Humans; Middle Aged; Multiple Myeloma; Oxides; Recurrence | 2006 |
A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oxides; Pyrazines; Recurrence; Survival Analysis; Treatment Failure; Treatment Outcome | 2007 |
Therapeutic potential of arsenic trioxide with or without interferon-alpha for relapsed/refractory adult T-cell leukemia/lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Disease Progression; Female; Humans; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; Male; Oxides; Recurrence; Salvage Therapy; Thrombocytopenia | 2007 |
Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.
Topics: Abdominal Pain; Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Constipation; Dermatitis; Dose-Response Relationship, Drug; Female; Headache; Humans; Hyperglycemia; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Lymphoma; Male; Nausea; Oxides; Pancreatitis; Pneumonia; Recurrence; Time Factors; Vomiting; Water-Electrolyte Balance | 2008 |
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Metabolic Clearance Rate; Middle Aged; Neutrophils; Oxides; Receptors, Retinoic Acid; Recurrence; Remission Induction; Retinoic Acid Receptor alpha; Survival Rate; Time Factors | 1997 |
New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Retinoids; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured | 1997 |
Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Disease-Free Survival; Drug Monitoring; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Oxides; Recurrence; Remission Induction; Translocation, Genetic | 1999 |
Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Death, Sudden; Female; Humans; Kinetics; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence | 2001 |
87 other study(ies) available for arsenic trioxide and Recrudescence
| Article | Year |
|---|---|
Relapsed/refractory acute promyelocytic leukemia with RARA-LBD region mutation was salvaged by venetoclax: A case report.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Bridged Bicyclo Compounds, Heterocyclic; Ecchymosis; Female; Humans; Leukemia, Promyelocytic, Acute; Mutation; Proto-Oncogene Proteins c-bcl-2; Recurrence; Salvage Therapy; Sulfonamides; Treatment Outcome; Tretinoin | 2021 |
Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 Activation.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; NF-E2-Related Factor 2; Oxides; Reactive Oxygen Species; Recurrence; Sulfonamides | 2022 |
Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Cytarabine; Follow-Up Studies; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Recurrence; Remission Induction; Treatment Outcome; Tretinoin | 2022 |
Intracranial bleeding in acute promyelocytic leukemia treated with arsenic trioxide based regimens is associated with induction mortality but not with relapse.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin | 2023 |
Two successful deliveries of healthy children by a young woman diagnosed and treated during induction and relapsed therapy for acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Pregnancy; Recurrence; Tretinoin; Young Adult | 2020 |
[Acute promyelocytic leukemia recurrence diagnosed due to granulocytic sarcoma of the external auditory canal].
Topics: Arsenic Trioxide; Ear Canal; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Recurrence; Sarcoma, Myeloid; Tretinoin | 2020 |
Relapse of acute promyelocytic leukemia in the external auditory canal confirmed by PML/RARA dual-fusion and RARA break-apart fluorescence in situ hybridization.
Topics: Abnormal Karyotype; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; DNA Probes; Ear Canal; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Positron-Emission Tomography; Recurrence; RNA, Messenger; RNA, Neoplasm; Tomography, X-Ray Computed; WT1 Proteins | 2018 |
Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia.
Topics: 5'-Nucleotidase; Animals; Antineoplastic Agents; Arsenic Trioxide; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Promyelocytic, Acute; Male; Mice; Mutation; Promyelocytic Leukemia Protein; Recurrence; Retinoic Acid Receptor alpha; Tretinoin | 2018 |
[Relationship between the Therapeutic Dose of Arsenic Trioxide and Relapse in Acute Promyelocytic Leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Retrospective Studies; Tretinoin | 2018 |
Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Drug Evaluation; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Proportional Hazards Models; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult | 2018 |
Long-term effect of all-trans retinoic acid and arsenic trioxide sequential maintenance in patients with acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Consolidation Chemotherapy; Female; Humans; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Prognosis; Recurrence; Retreatment; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome; Tretinoin | 2019 |
Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy.
Topics: Abnormal Karyotype; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Child; Child, Preschool; Chromosome Aberrations; Cytogenetic Analysis; Female; Humans; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; Prognosis; Recurrence; Treatment Outcome; Young Adult | 2019 |
Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bone Marrow; Clone Cells; Disease Progression; Drug Resistance, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Promyelocytic, Acute; Mutation; Neoplasm Proteins; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Promyelocytic Leukemia Protein; Protein Domains; Recurrence; Remission Induction; Reproducibility of Results; Retinoic Acid Receptor alpha; RNA, Messenger; RNA, Neoplasm; Tretinoin | 2019 |
Role of hematopoietic stem cell transplantation for relapsed acute promyelocytic leukemia: a retrospective analysis of JALSG-APL97.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Combined Modality Therapy; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Japan; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Retrospective Studies; Salvage Therapy; Tetrahydronaphthalenes; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Tretinoin; Young Adult | 2013 |
Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; China; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Dexamethasone; Drug Evaluation; Female; Harringtonines; Homoharringtonine; Humans; Idarubicin; Infusions, Intravenous; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult | 2014 |
Outcomes and prognostic factors of first relapsed acute promyelocytic leukemia patients undergoing salvage therapy with intravenous arsenic trioxide and chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Drug Evaluation; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prognosis; Proportional Hazards Models; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Young Adult | 2014 |
Treatment of an acute promyelocytic leukemia relapse using arsenic trioxide and all-trans-retinoic in a 6-year-old child.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin | 2014 |
Oral arsenic trioxide-based regimen as salvage treatment for relapsed or refractory mantle cell lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Humans; Lymphoma, Mantle-Cell; Middle Aged; Oxides; Positron-Emission Tomography; Recurrence; Salvage Therapy; Survival Analysis | 2014 |
Resistance to therapy in acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Mutation; Oncogene Proteins, Fusion; Oxides; Recurrence; Tretinoin | 2014 |
Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Canada; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Leukemia, Promyelocytic, Acute; Male; Markov Chains; Middle Aged; Monte Carlo Method; Oxides; Quality-Adjusted Life Years; Recurrence; Treatment Failure; Treatment Outcome; Tretinoin | 2015 |
Extramedullary relapse in RARA rearrangement-negative acute promyelocytic leukemia successfully treated in combination with chemotherapy, local radiotherapy, and cord blood transplantation.
Topics: Allografts; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Female; Gene Rearrangement; Humans; Infant; Leukemia, Promyelocytic, Acute; Oxides; Receptors, Retinoic Acid; Recurrence; Retinoic Acid Receptor alpha | 2015 |
Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Child; Child, Preschool; Disease-Free Survival; Europe; Female; Humans; International Cooperation; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prospective Studies; Recurrence; Registries; Treatment Outcome; Young Adult | 2015 |
Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Granulocyte Precursor Cells; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Prospective Studies; Recurrence; Transcription Factors; Tretinoin; Tumor Suppressor Proteins; Young Adult | 2015 |
[The clinical efficacy of all-trans retinoic acid plus arsenic trioxide in 177 newly diagnosed acute promyelocytic leukemia patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Tretinoin | 2015 |
Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Frequency; Humans; Leukemia, Promyelocytic, Acute; Longitudinal Studies; Male; Middle Aged; Mutation, Missense; Oncogene Proteins, Fusion; Oxides; Recurrence; Young Adult | 2015 |
[Relapse of acute promyelocytic leukemia in the central nervous system revealed by isolated dementia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Dementia; Female; Humans; Leukemia, Promyelocytic, Acute; Meningeal Neoplasms; Neoplasm Recurrence, Local; Oxides; Recurrence; Remission Induction | 2016 |
Autologous transplant remains the preferred therapy for relapsed APL in CR2.
Topics: Adolescent; Adult; Aged; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Infant; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Young Adult | 2016 |
Autologous hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission: outcomes before and after the introduction of arsenic trioxide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Japan; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2017 |
Acute promyelocytic leukemia: recent advances in diagnosis and management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Salvage Therapy; Treatment Outcome; Tretinoin | 2008 |
Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Cytarabine; Female; Humans; Injections, Spinal; Leukemia, Promyelocytic, Acute; Male; Methotrexate; Middle Aged; Oxides; Recurrence | 2008 |
Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia.
Topics: Arsenic Trioxide; Arsenicals; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Leukemia, Promyelocytic, Acute; Male; Mass Spectrometry; Middle Aged; Oxides; Recurrence; Remission Induction; Time Factors; Tretinoin | 2009 |
Successful pregnancy after arsenic trioxide therapy for relapsed acute promyelocytic leukaemia.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Infant, Newborn; Leukemia, Promyelocytic, Acute; Male; Oxides; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Recurrence | 2009 |
Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Child; Combined Modality Therapy; Female; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Myeloablative Agonists; Oncogene Proteins, Fusion; Oxides; Peripheral Blood Stem Cell Transplantation; Recurrence; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Tretinoin; Young Adult | 2009 |
Relapsed APL patient with variant NPM-RARalpha fusion responded to arsenic trioxide-based therapy and achieved long-term survival.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction | 2010 |
CNS relapse in acute promyeloctyic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Neoplasms; Brain Neoplasms; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cranial Irradiation; Cytarabine; Drug Administration Schedule; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Magnetic Resonance Imaging; Mercaptopurine; Methotrexate; Mutation; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Recurrence; Remission Induction; Retinoic Acid Receptor alpha; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factors; Translocation, Genetic; Transplantation, Autologous; Treatment Outcome; Tretinoin; Tumor Suppressor Proteins | 2010 |
[Arsenic trioxide treatment in a patient with recurrent acute promyelocytic leukemia (APL)].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence | 2010 |
Clinical efficacy of arsenic trioxide in a patient with acute promyelocytic leukemia with recurrent central nervous system involvement.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Central Nervous System; Central Nervous System Neoplasms; Female; Humans; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Meningeal Neoplasms; Oxides; Recurrence; Treatment Outcome | 2011 |
Utilization of molecular phenotypes to detect relapse and optimize the management of acute promyelocytic leukemia.
Topics: Adaptor Proteins, Signal Transducing; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Phenotype; Prognosis; Recurrence; Translocation, Genetic; Tretinoin | 2010 |
Long-term remission after first-line single-agent treatment with arsenic trioxide of relapsed acute promyelocytic leukemia in an 8-year-old boy.
Topics: Arsenic Trioxide; Arsenicals; Child; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence; Remission Induction; Time Factors | 2011 |
Arsenic trioxide for the treatment of a relapsed acute promyelocytic leukemia with acute renal failure.
Topics: Acute Kidney Injury; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Fatal Outcome; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence | 2011 |
Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Treatment Outcome; Tretinoin | 2011 |
Oral arsenic trioxide for relapsed acute promyelocytic leukemia in pediatric patients.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence; Time Factors | 2012 |
Sustained molecular remission after arsenic trioxide and gemutuzumab ozogamicin in a pediatric patient with relapsed acute promyelocytic leukemia.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; Benzoates; Child; Drug Administration Schedule; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence; Remission Induction; Tetrahydronaphthalenes; Tretinoin | 2012 |
Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Staging; Oxides; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Treatment Outcome; Tretinoin; Young Adult | 2012 |
Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prognosis; Recurrence | 2013 |
[Management of relapsed acute promyelocytic leukemia].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Brain; Humans; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Oxides; Recurrence; Tetrahydronaphthalenes | 2012 |
Atypical blasts and bone marrow necrosis associated with near-triploid relapse of acute promyelocytic leukemia after arsenic trioxide treatment.
Topics: Adult; Arsenic Trioxide; Arsenicals; Biopsy; Bone Marrow; Chromosome Aberrations; Fatal Outcome; Female; Humans; Karyotyping; Leukemia, Promyelocytic, Acute; Necrosis; Oxides; Ploidies; Recurrence | 2002 |
Real-time quantification of the multidrug resistance-1 gene expression in relapsed acute promyelocytic leukemia treated with arsenic trioxide.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dose-Response Relationship, Drug; Female; Genes, MDR; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Reverse Transcriptase Polymerase Chain Reaction | 2002 |
Molecular remission and reconstitution of a full chimera with arsenic trioxide in a patient with acute promyelocytic leukemia relapsed after allogeneic bone marrow transplantation.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Molecular Diagnostic Techniques; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; RNA, Neoplasm; Salvage Therapy; Transplantation Chimera; Transplantation, Homologous | 2002 |
[Successful treatment after acute promyelocytic leukemia (APL) syndrome of relapsed API with arsenic trioxide].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Female; Humans; Informed Consent; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Recurrence; Remission Induction | 2003 |
Prolonged molecular remission after arsenic trioxide and all-trans retinoic acid for acute promyelocytic leukemia relapsed after allogeneic stem cell transplantation.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Tretinoin | 2003 |
45th Annual Meeting of the American Society of Hematology December 6-9, 2003.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Hematology; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multicenter Studies as Topic; Multiple Myeloma; Oxides; Prognosis; Protein-Tyrosine Kinases; Recurrence; Risk; Rituximab; Salvage Therapy; Thalidomide; Time Factors; ZAP-70 Protein-Tyrosine Kinase | 2004 |
Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Child, Preschool; Combined Modality Therapy; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Remission Induction | 2004 |
Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Female; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Middle Aged; Oxides; Recurrence; Tretinoin | 2004 |
Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma.
Topics: Aged; Antineoplastic Agents, Alkylating; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Oxides; Recurrence; Treatment Outcome | 2005 |
Successful treatment of relapsed acute promyelocytic leukemia in a patient receiving continuous ambulatory peritoneal dialysis with oral arsenic trioxide.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Peritoneal Dialysis, Continuous Ambulatory; Recurrence; Treatment Outcome | 2005 |
Arsenic trioxide in the treatment of relapsed and refractory acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Japan; Leukemia, Promyelocytic, Acute; Oxides; Recurrence | 2005 |
Frequent varicella zoster reactivation associated with therapeutic use of arsenic trioxide: portents of an old scourge.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Chickenpox; Child; Female; Herpes Zoster; Humans; Male; Middle Aged; Oxides; Recurrence | 2005 |
Current management and new approaches in the treatment of APL.
Topics: Aminoglycosides; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Drug Monitoring; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Stem Cell Transplantation; Tretinoin | 2003 |
[Acute pancreatitis during the treatment of relapsed acute promyelocytic leukemia with As2O3].
Topics: Acute Disease; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Pancreatitis; Recurrence | 2006 |
The incidence of recurrent herpes simplex and herpes zoster infection during treatment with arsenic trioxide.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Colonic Neoplasms; Female; Herpes Simplex; Herpes Zoster; Humans; Male; Multiple Myeloma; Oxides; Recurrence | 2006 |
Elemental arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia.
Topics: Administration, Oral; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Meningeal Neoplasms; Middle Aged; Oxides; Recurrence | 2006 |
Recurrent extramedullary relapse of acute promyelocytic leukemia after allogeneic stem cell transplantation: successful treatment by arsenic trioxide in combination with local radiotherapy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Combined Modality Therapy; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Radiography; Recurrence; Remission Induction; Sarcoma, Myeloid; Stem Cell Transplantation; Translocation, Genetic; Transplantation, Homologous; Tretinoin | 2006 |
Real-time PCR analysis of PML-RAR alpha in newly diagnosed acute promyelocytic leukaemia patients treated with arsenic trioxide as a front-line therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Child; Early Diagnosis; Female; Follow-Up Studies; Gene Expression; Glucosephosphate Dehydrogenase; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Oncogene Proteins, Fusion; Oxides; Protein Isoforms; Recombinant Fusion Proteins; Recurrence; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Disease-Free Survival; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Survival Rate; Tretinoin | 2007 |
Current treatment of acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Clinical Trials as Topic; Computer Systems; Disease Management; Drug Monitoring; Hematopoietic Stem Cells; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Mice; Multicenter Studies as Topic; Oncogene Proteins, Fusion; Oxides; Polymerase Chain Reaction; Predictive Value of Tests; Recurrence; Sensitivity and Specificity; Transfection; Tretinoin | 2007 |
Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia/lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Central Nervous System Neoplasms; Diphtheria Toxin; Drug Resistance, Neoplasm; Hematologic Neoplasms; Humans; Interferons; Interleukin-2; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Oxides; Recombinant Fusion Proteins; Recurrence; Remission Induction; Transplantation, Homologous; Zidovudine | 2007 |
Simultaneous appearance of central nervous system relapse and subarachnoid hemorrhage during the treatment for acute promyelocytic leukemia.
Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Combined Modality Therapy; Endothelium, Vascular; Gemtuzumab; Humans; Injections, Spinal; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Magnetic Resonance Imaging; Male; Meninges; Middle Aged; Oxides; Postoperative Complications; Recurrence; Subarachnoid Hemorrhage; Tomography, X-Ray Computed | 2008 |
Hyperleukocytosis from arsenic trioxide.
Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Oxides; Recurrence | 2008 |
Retrospective analysis of 65 Chinese children with acute promyelocytic leukemia: a single center experience.
Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Humans; Infant; Leukemia, Promyelocytic, Acute; Male; Oxides; Prognosis; Recurrence; Retrospective Studies; Treatment Outcome; Tretinoin | 2008 |
PML targeting eradicates quiescent leukaemia-initiating cells.
Topics: Adult; Animals; Arsenic Trioxide; Arsenicals; Cell Line; Coculture Techniques; Female; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Inbred C57BL; Neoplastic Stem Cells; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Recurrence; Regeneration; Transcription Factors; Tumor Suppressor Proteins | 2008 |
Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.
Topics: Adolescent; Adult; Aged; Antigens, CD; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Caspases; Cell Differentiation; Child; Humans; Immunophenotyping; Leukemia, Promyelocytic, Acute; Leukocytes, Mononuclear; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction | 1998 |
Acute promyelocytic leukemia: a curable disease.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Drug Resistance; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Karyotyping; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neoplasm, Residual; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Recurrence; Research; Rome; Transcription Factors; Tretinoin; Tumor Suppressor Proteins | 1998 |
Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia.
Topics: Acute Disease; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Chronic Disease; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence | 1998 |
Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Humans; Leukemia, Promyelocytic, Acute; Male; Neoplasms, Second Primary; Oxides; Recurrence; Transplantation, Autologous; Tretinoin | 1999 |
Successful treatment with arsenic trioxide of a patient with ATRA-resistant relapse of acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Chromosome Banding; Colony-Forming Units Assay; Drug Resistance, Neoplasm; Feeding and Eating Disorders; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Metaphase; Middle Aged; Musculoskeletal Diseases; Oxides; Pain; Polymerase Chain Reaction; Recurrence; Tretinoin | 1999 |
Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Binding Sites; Bone Marrow; Carrier Proteins; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Ligands; Male; Middle Aged; Mutation, Missense; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Point Mutation; Protein Structure, Tertiary; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tretinoin | 1999 |
Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin | 2000 |
Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Electrocardiography, Ambulatory; Female; Humans; Leukemia, Promyelocytic, Acute; Long QT Syndrome; Male; Middle Aged; Oxides; Prospective Studies; Recurrence; Remission Induction; Tachycardia, Ventricular | 2000 |
Hyperleukocytosis during induction therapy with arsenic trioxide for relapsed acute promyelocytic leukemia associated with central nervous system infarction.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Infarction; Fatal Outcome; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides; Recurrence; Remission Induction | 2000 |
Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia.
Topics: Adolescent; Adult; Arsenic Trioxide; Arsenicals; Female; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence | 1998 |
Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Drug Evaluation; Drug Synergism; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Pilot Projects; Prospective Studies; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Salvage Therapy; Treatment Outcome | 2001 |
Central nervous system relapse in a patient with acute promyelocytic leukaemia treated with arsenic tri-oxide.
Topics: Adult; Animals; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Central Nervous System Diseases; Choroid Plexus; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence | 2001 |
Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence | 2001 |
Successful treatment of a case of relapsed acute promyelocytic leukemia with arsenic trioxide.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Treatment Outcome | 2001 |
[Seven years' summary report on the treatment of acute promyelocytic leukemia with arsenic trioxide--an analysis of 242 cases].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Survival Rate | 2000 |
Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence; Remission Induction; Tretinoin | 2002 |